Lakewood-Amedex Biotherapeutics Inc. (LABT)
LABT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | LABT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0002079272 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed financial statements are issued." | 10-Q 2026-08-14 |
| Cash and burn | $2.6M cash; operating cash flow -$842K a quarter. | Report 2026-06-30 |
| Shares outstanding | 2,369,688 (2026-08-03). | Cover page 2026-08-03 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2026-06-22 | Source 2026-06-22 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Tampa, Florida, United States | PCAOB Form AP 2026-09-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$3.8M | -$2.1M | $2.6M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q2 2026 2026-03-31 | Not filed | -$923K | -$350K | $12K | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q2 2026 2025-06-30 | Not filed | -$656K | -$509K | $1.3M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q2 2026 2025-03-31 | Not filed | -$540K | -$404K | $477K | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-1 | 2026-09-18 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-16 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-08-10 |
Source: SEC EDGAR submissions feed, 47 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -28.2% |
| 1 month | -59.4% |
| 3 months | -88.0% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -99.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CDT | CDT Equity Inc. | $0.3770 | -5.84% | $384K |
| SPRC | SciSparc Ltd. | $0.3307 | -10.62% | $815K |
| OGEN | Oragenics Inc. | $0.1980 | -1.49% | $893K |
| MTNB | Matinas Biopharma Holdings Inc. | $0.9270 | +3.00% | $908K |
| GOVX | GeoVax Labs Inc. | $2.02 | +18.48% | $1.1M |
| BDRX | Biodexa Pharmaceuticals plc American Depositary Shs | $2.24 | -6.28% | $1.2M |
| ELAB | PMGC Holdings Inc. | $1.66 | +5.06% | $1.3M |
| KAPA | Kairos Pharma Ltd. | $0.4069 | -10.30% | $1.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier